Protocols

BioMarin looks for fast approval of hemophilia A gene therapy; Investigators tout Entasis antibiotic

BioMarin $BMRN told analysts during its R&D day that new FDA rules may make it possible to file for an FDA approval on its hemophilia A gene therapy valrox, if the Phase I/II study continues as expected.

→ Investigators involved in a Phase II study of a new antibiotic say that a single oral dose worked in treating gonorrhea. Zoliflodacin — developed by Entasis — works by inhibiting DNA biosynthesis.

→ The UK’s Vectura (LSE: $VEC) has inked a deal to work with Hikma on a generic version of GSK’s Ellipta. Vectura gets $15 million upfront with another $80 million in milestones.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->